Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Iloprost

Iloprost

Iloprost is a synthetic prostacyclin (PGI2) analog used to treat pulmonary arterial hypertension and peripheral artery disease.
It acts as a vasodilator, inhibitor of platelet aggregation, and cytoprotective agent.
Iloprost has been shown to improve exercise capacity and hemodynamic parameters in clinical studies.
Researchers can optimize their Iloprost studies using PubCompare.ai, an AI-driven platform that helps locate protocols from literature, preprints, and patents, while providing accurate comparisons to identify the best protocols and products.
This cutting-edge solution enables reproducible, acurate studies for Iloprost and other therapeutics.

Most cited protocols related to «Iloprost»

1
Systemic Sclerosis Validation Cohorts
Cited 4 times
The validation cohorts were constituted of a cumulative number of 219 patients. All enrolled patients met the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for SSc [2 (link)], and they were also sub-classified as having limited cutaneous systemic sclerosis (lcSSc) or diffuse cutaneous systemic sclerosis (dcSSc) following the LeRoy et al. criteria [10 (link)]. Exclusion criteria were concomitant conditions that may potentially cause additional microvascular changes, such as diabetes, smoking and onychophagic habitus; presence of anti-phospholipid antibodies; and pregnancy. Current treatment with beta-blockers was also an exclusion criterion because it is well known that this drug may cause or exacerbate Raynaud’s phenomenon (RP).
At the time of study enrolment, 52 of the 219 patients were receiving treatment with infusions of intravenous prostanoids (45 with monthly iloprost and 7 with weekly alprostadil), and 16 were taking bosentan. It was decided for ethical reasons to continue the vasodilatory treatments for the prospectively enrolled patients in Milan. Furthermore, all of the patients were receiving stable treatment with low-dose acetylsalicylic acid and calcium channel blockers.
One hundred twenty-two patients with SSc who were referred to the rheumatic disease unit of the Gaetano Pini Institute of Milan formed the prospectively collected internal validation cohort. It was preliminarily established to consecutively include around half the patients with inactive disease (ESSG score <3 and a similar proportion of patients with active disease [ESSG score ≥3]). This cohort did not include any patient who had been recruited for the previous study [7 (link)].
Ninety-seven patients with SSc who were referred to the rheumatology unit of the 2nd University of Naples formed the external validation cohort. These patients and their NVC images were randomly selected from the database on the condition that about one-third of them should have an ESSG score ≥3.
Andracco R., Irace R., Zaccara E., Vettori S., Maglione W., Riccardi A., Pignataro F., Ferrara R., Sambataro D., Sambataro G., Vitali C., Valentini G, & Del Papa N. (2017). The cumulative number of micro-haemorrhages and micro-thromboses in nailfold videocapillaroscopy is a good indicator of disease activity in systemic sclerosis: a validation study of the NEMO score. Arthritis Research & Therapy, 19, 133.
Full text: Click here
Publication 2017
Adrenergic beta-Antagonists Alprostadil Antiphospholipid Antibodies Aspirin Bosentan Calcium Channel Blockers Collagen Diseases Diabetes Mellitus Diffuse Scleroderma Europeans Iloprost Intravenous Infusion Patients Pharmaceutical Preparations Pregnancy Prostaglandins Raynaud Phenomenon Rheumatism Systemic Scleroderma Vasodilation
2
Investigating CGRP Regulation in OA Synovial Cells
Cited 3 times
To investigate the factors regulating CGRP and CGRP receptor expression, synovial cells were harvested from synovium collected from the knees of 12 OA patients. Mononuclear cells were isolated from synovium by digestion of the tissue with 40 ml of 0.1 % type I collagenase. The obtained cells were cultured in α-MEM in 6-well plates. After 7 days, the cells harvested from six patients were stimulated with human recombinant IL-6 (100 ng/ml), IL-1β (50 ng/ml), TNF-α (10 ng/ml), or PGE2 (10 μM) for 24 h. The cells harvested from another six patients were stimulated with 10 μM iloprost, butaprost, sulprostone, or CAY10598 for 24 h. After the treatments, cells were harvested for RNA isolation, as described above, and CGRP, RAMP1, and CLR expression was analyzed by RT-PCR. Cells were also harvested for protein extraction, as described below, and RAMP1 protein expression was analyzed by Western blotting.
Minatani A., Uchida K., Inoue G., Takano S., Aikawa J., Miyagi M., Fujimaki H., Iwase D., Onuma K., Matsumoto T, & Takaso M. (2016). Activation of calcitonin gene-related peptide signaling through the prostaglandin E2-EP1/EP2/EP4 receptor pathway in synovium of knee osteoarthritis patients. Journal of Orthopaedic Surgery and Research, 11, 117.
Full text: Click here
Publication 2016
butaprost Calcitonin-Gene Related Peptide Receptor CAY10598 Cells Collagenase, Clostridium histolyticum Digestion Dinoprostone Homo sapiens Iloprost Interleukin-1 beta isolation Knee Patients Proteins Reverse Transcriptase Polymerase Chain Reaction sulprostone Synovial Membrane Synoviocytes Tissues Tumor Necrosis Factor-alpha
3
Iloprost Chemoprevention for Lung Cancer
Cited 3 times
The iloprost lung cancer chemoprevention study was a multicenter, phase II, randomized, double-blind, placebo-controlled trial of iloprost in subjects at increased risk for lung cancer (defined as current or former smokers with 20 pack year or more smoking history, at least mild sputum cytologic atypia, or a history of biopsy proven endobronchial dysplasia). The majority of subjects were recruited from pulmonary medicine clinics. Exclusion criteria included prior history of cancer, significant comorbid disease or inability to undergo 2 bronchoscopies, hypoxemia with the required use of supplemental oxygen, use of inhaled steroids within 6 weeks of trial enrollment, and carcinoma in situ or invasive cancer on endobronchial biopsy. Sputum was collected and cytology was graded by a single cytopathologist (W. A. Franklin) as previously published (18 (link)). Autofluorescence and/or white light bronchoscopy was carried out before randomization and after 6 months of treatment, with 6 standard endobronchial sites biopsied (all were carini, identified as RUL, RML, RB6, LUL, LUDB, and LB6), along with all other visually suspicious appearing areas.
The trial sample size was 152 subjects and, after obtaining written informed consent, participants were block randomized based on smoking status (current vs. former) and study center. The randomization sequence was generated prior to trial initiation and stored in a password-protected spreadsheet accessible only to the trial biostatistician and study administrator. Subjects were randomized only after confirmation of eligibility, and blinding was maintained throughout the trial. Following randomization, subjects were started on either iloprost or placebo at an initial dose of 1 tablet BID (50 μg iloprost clathrate per tablet). The subjects had a monthly clinical evaluation and if well tolerated, iloprost or placebo was dose escalated by 1 tablet monthly to a maximum dose of 3 tablets BID. Following 6 months of treatment, a second bronchoscopy was carried out with repeat biopsies at all of the baseline sites. Adverse events were monitored and reported twice yearly to an independent data and safety monitoring board (DSMB). A final clinical visit occurred 1 month after completing the trial and subjects are currently undergoing passive follow-up (i.e., yearly questionnaires). The trial involved 7 clinical centers (listed in the Appendix) funded by the National Cancer Institute as the Lung Cancer Biomarkers and Chemoprevention Consortium and individual site SPORE grants. The institutional review boards at each study center approved the study protocol. This trial was listed and registered on ClinicalTrials.gov (Identifier: NCT00084409). Bayer-Schering Pharma AG (Berlin) provided the study medication and placebo tablets.
Keith R.L., Blatchford P.J., Kittelson J., Minna J.D., Kelly K., Massion P.P., Franklin W.A., Mao J., Wilson D.O., Merrick D.T., Hirsch F.R., Kennedy T.C., Bunn PA J.r., Geraci M.W, & Miller Y.E. (2011). Oral Iloprost Improves Endobronchial Dysplasia in Former Smokers. Cancer Prevention Research (Philadelphia, Pa.), 4(6), 793-802.
Publication 2011
Administrators Biological Markers Biopsy Bronchoscopy Carcinoma in Situ Chemoprevention Clinical Trials Data Monitoring Committees Cytological Techniques Eligibility Determination Ethics Committees, Research Iloprost Light Lung Lung Cancer Malignant Neoplasms Oxygen Pharmaceutical Preparations Placebos Spores Sputum Steroids Tumor Markers
4
Isolation and Culture of Pulmonary Artery Smooth Muscle Cells
Cited 3 times
Lung tissues were obtained at lung transplantation (emphysema n = 8; pulmonary fibrosis n = 2; unused donor n = 1) and at lobectomy or pneumonectomy for bronchial carcinoma (n = 3), with informed consent and local approval from Hammersmith and Brompton-Harefield Hospitals ethics committees. Distal pulmonary artery smooth muscle cells (PASMCs) were isolated from micro-dissected segments of artery (<1 mm external diameter), as previously described [7 (link)]. Explants were placed in Dulbecco's modified Eagle medium (DMEM) containing 20% (v/v) foetal bovine serum (FBS) and 1% (v/v) antibiotic/antimycotic at 37°C, 5% CO2. Cells were maintained in DMEM containing 5–10% FBS and used at passages 3–12. For experiments confluent cells were made quiescent by incubation with serum-free media for 48 h and responses to platelet-derived growth factor (PDGF)-BB (5–10 ng/ml), prostacyclin analogues (cicaprost, iloprost) and PDE inhibitors were determined, as described below. When confluent, these cell isolates formed sheets of spindle-shaped cells and, like smooth muscle cells in the medial layer of intact distal human pulmonary arteries, expressed α-smooth muscle actin, calponin, endothelin ETA and ETB receptors and phosphodiesterase type 5 [7 (link),34 (link)].
Growcott E.J., Spink K.G., Ren X., Afzal S., Banner K.H, & Wharton J. (2006). Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells. Respiratory Research, 7(1), 9.
Full text: Click here
Publication 2006
Actins Antibiotics Arteries Becaplermin Bronchogenic Carcinoma calponin Cells cicaprost Culture Media, Serum-Free Cyclic Nucleotide Phosphodiesterases, Type 5 Eagle Endothelin Epoprostenol Ethics Committees, Clinical Fetal Bovine Serum Homo sapiens Iloprost Lung Lung Transplantation Myocytes, Smooth Muscle Phosphodiesterase Inhibitors Pneumonectomy Pulmonary Artery Pulmonary Emphysema Pulmonary Fibrosis Smooth Muscles Tissue Donors Tissues
5
Invasive Hemodynamic Assessment in PH
Cited 2 times
Demographic and clinical data were retrieved from each patient's electronic medical record. Past medical history, percutaneous oxygen saturation (SpO2), and laboratory values for brain natriuretic peptide (BNP) were collected before each RHC, as well as echocardiographic data including peak tricuspid regurgitation velocity (TRV), maximal main pulmonary artery and aortic diameter, biventricular size and function, and the presence of pericardial effusion. Invasive hemodynamic data were obtained by RHC in the cardiac catheterization laboratory, including PAP and invasive systemic blood pressure (SBP), right atrial pressure, cardiac output (estimated using the indirect Fick method), PVR, and PVR index and acute pulmonary vasoreactivity testing result (iloprost inhalation or supplemental oxygen at flow rate of 5 L/min with oxygen mask) if available; inhaled iloprost was administered at a dose of 20 µg, with the exception of children aged <3 years or those weighing <15 kg who received 10 µg. Arterial blood gas analysis was performed following femoral artery catheter insertion. Continuous percutaneous oxygen saturations and SBP by femoral arterial line during the procedure were recorded. All baseline hemodynamic data were acquired in room air and supplemental oxygen was used only to treat acute desaturation. Procedural data included procedure duration, types of anesthetics administered, airway management, and adverse events occurring during the procedure or before discharge home.
PHC was defined as a rapid decrease both in SBP (systolic pressure lower than 80 mmHg or an absolute decrease >20%) and SpO2 (lower than 90%), and acute increase to supra‐systemic PAP during RHC. Other complications such as hypotensive episodes related to vagal reactions or acute vasoreactivity testing were excluded if oxygen saturation and hemodynamics were unchanged. Transient desaturation due to respiratory insufficiency was also not considered as PHC. We obtained follow‐up data from in/out‐patient medical records or telephone interviews.
Li Q., Zhang C., Wang R., Keller B.B, & Gu H. (2022). Pulmonary hypertensive crisis in children with pulmonary arterial hypertension undergoing cardiac catheterization. Pulmonary Circulation, 12(2), e12067.
Publication 2022
Airway Management Anesthetics Aorta Arterial Lines Arteries Atrium, Right Blood Gas Analysis Cardiac Output Catheterization Catheterizations, Cardiac Child, Exceptional Echocardiography Effusion, Pericardial Femoral Artery Femur Hemodynamics Iloprost Lung Nesiritide Outpatients Oxygen Oxygen Saturation Patient Discharge Pressure Pulmonary Artery Respiratory Insufficiency Saturation of Peripheral Oxygen Systolic Pressure Transients Tricuspid Valve Insufficiency Vasovagal Syncope

Most recents protocols related to «Iloprost»

1
Retrospective Study of Pulmonary Arterial Hypertension
We retrospectively collected and studied adult treatment-naive patients with IPAH or PAH-CHD who were admitted to the Second Xiangya Hospital from November 2011 to June 2020. All recruited patients with IPAH or PAH-CHD met the following diagnostic criteria: mPAP ≥ 25 mmHg, PVR >3 WU and PAWP ≤15 mmHg during resting RHC (Galiè et al., 2016 (link)). Except for IPAH and PAH-CHD, patients with other types of PAH or PH belonging to groups 2–5 were also excluded. All recruited patients were prescribed PAH-specific therapy based on multiparameter risk stratification of contemporaneous guidelines, and cardiac function and haemodynamics parameters were assessed by means of echocardiography. In the 2022 ESC/ERS guideline for pulmonary hypertension, it was recommended to use a three-strata risk-assessment model to classify patients as low, intermediate, or high risk at initial assessment, and to use a four-strata model to classify patients as low, intermediate-low, intermediate-high, or high risk during follow-up (Humbert et al., 2022 (link)). Risk stratification can help guides treatment decisions in patients with PAH. Briefly, initial monotherapy with PDE-5i or ERAs was recommended for patients with PAH and cardiopulmonary comorbidities. In patients with PAH without cardiopulmonary complications, initial dual combination therapy of ERAs and PDE-5i was recommended for patients with low- or intermediate-risk of death, and triple combination therapy of ERAs, PDE-5i, and prostacyclin analogue is recommended for patients with high-risk of death. At follow-up, patients who reach low-risk status continued the initial regimen, and patients with medium-low risk were suggested to add prostacyclin receptor agonist or replace PDE-5i to sGC. In addition, intravenous or subcutaneous prostacyclin or evaluation for lung transplantation was recommended for patients who had insufficient treatment response and were still at intermediate-high or even high risk. PAH-specific medications in this study included PDE-5i (e.g., sildenafifil and tadalafifil), ERAs (e.g., bosentan, ambrisentan, and macitentan), prostacyclin analogues (e.g., intravenous or subcutaneous treprostinil, intravenous epoprostenol, and inhaled iloprost), prostacyclin receptor agonists (slexipag), and sGCs (e.g., riociguat). The study was approved by the Ethics Committee of the Second Xiangya Hospital.
Zhu T., Wu P., Tan Z., Jin Q., Chen Y., Li L., Chen Z., Tang Y., Li J, & Fang Z. (2023). Differences in right ventricular function and response to targeted therapy between patients with IPAH and PAH-CHD. Frontiers in Pharmacology, 14, 1124746.
Full text: Click here
Publication 2023
Adult agonists ambrisentan Bosentan Combined Modality Therapy Diagnosis Echocardiography Epoprostenol estrogen receptor alpha, human Ethics Committees, Clinical Health Risk Assessment Heart Hemodynamics Iloprost Lung Transplantation macitentan Patients Pulmonary Hypertension Pulmonary Wedge Pressure Receptors, Epoprostenol riociguat Treatment Protocols treprostinil
2
Systemic Sclerosis Protocol: Comprehensive Evaluation
Forty-three SSc patients followed at Siena University Hospital were consecutively enrolled from September 2020 to June 2021. Patients fulfilling 2013 ACR/EULAR SSc classification criteria were enrolled [5 (link)]. The following data were collected for each patient: age, sex, body mass index (BMI), smoking history, hypertension, disease duration, DU (active DU or previous healed DU), modified Rodnan skin score (mRSS), type of cutaneous involvement (limited/diffuse), serum anticentromere antibodies (ACA), anti PM/Scl antibodies, anti-topoisomerase I antibodies (Scl-70), pulmonary artery pressure (PAPs) expressed in mmHg and left ventricular ejection fraction (FE%) evaluated at echocardiography, diffusion capacity for carbon monoxide (DLCO), nailfold-video-capillaroscopy (NVC) pattern (early, active and late) and macrovascular CDUS parameters (RI and PV). Treatment at the time of the evaluation was reported: antiplatelet therapy, calcium channel blockers, iloprost, endothelin receptor antagonists (ERA), phosphodiesterase inhibitors, immunosuppressive treatment (mycophenolate mofetil, methotrexate, azathioprine, rituximab), nintedanib and steroids. The results from the SSc group were compared to those of a group of patients affected by primary RP (n = 23) and to HCs (n = 22). Data regarding RP and DU severity and diagnosis of pulmonary hypertension made by right heart catheterization were not evaluated. All patients were evaluated under vasodilator treatment except for those receiving iloprost, who were evaluated on a different day with respect to the treatment. All patients gave their own written informed consent. This study was specially approved by the ethical committee of “Azienda Ospedaliero Universitaria Senese” (protocol number: RHELABUS 22271).
D’Alessandro R., Garcia Gonzalez E., Falsetti P., Conticini E., d’Alessandro M., Selvi E., Bellisai F., Berlengiero V., Vallifuoco G., Pata A.P., Bardelli M., Baldi C., Cantarini L., Bargagli E, & Frediani B. (2023). Peripheral Macrovascular Involvement in Systemic Sclerosis: A Cohort Study by Color and Spectral Doppler Ultrasonography. Life, 13(2), 487.
Full text: Click here
Publication 2023
alpha 2-plasmin inhibitor-plasmin complex Anti-Antibodies anti-centromere antibodies anti-scl-70 autoantibodies Azathioprine Calcium Channel Blockers Catheterizations, Cardiac Diagnosis Diffusion Echocardiography Endothelin Receptor Antagonist High Blood Pressures Iloprost Immunosuppressive Agents Index, Body Mass Methotrexate Monoxide, Carbon Mycophenolate Mofetil Nailfold Capillaroscopy nintedanib Patients Phosphodiesterase Inhibitors Pressure Pulmonary Artery Pulmonary Hypertension Rituximab Serum Skin Steroids Vasodilator Agents Ventricular Ejection Fraction
3
Iloprost Inhalation Therapy for Lung Condition
Randomization was performed at a 1:1 ratio using a parallel group design. Randomization lists were generated at the biostatistical center using the software nQuery, release 4, and based on these lists, numbered envelopes were provided and used for randomization (stratified for center and using blocks of random length). For each center, a separate spate list was generated, and closed envelopes were supplied to the participating centers. Envelopes were opened only by the treating physician. The randomization number and treatment were recorded in the ID screening and enrollment list, dated and signed. The signed sheet was then stored at the participating center. Random treatment allocation was used to protect against selection bias. Concealment bias was not present, because the person who was recruiting patients was informed after recruitment about the assigned study arm. The primary and secondary endpoints were objectively measurable, which excluded information bias. Intervention was inhalation with Iloprost (20 µg/3times per day in 10 ml NaCl 0.9% for 5 days) or inhalation of NaCl 0.9% (10 ml) as Placebo [11 (link)].
Haeberle H.A., Calov S., Martus P., Serna-Higuita L.M., Koeppen M., Goll A., Bernard A., Zarbock A., Meersch M., Weiss R., Mehrländer M., Marx G., Putensen C., Bakchoul T., Magunia H., Nieswandt B., Mirakaj V, & Rosenberger P. (2023). Inhaled prostacyclin therapy in the acute respiratory distress syndrome: a randomized controlled multicenter trial. Respiratory Research, 24, 58.
Full text: Click here
Publication 2023
Iloprost Inhalation Normal Saline Patients Physicians Placebos
4
Cardiac Biomarkers and Pulmonary Function in Systemic Sclerosis
All participants underwent two CMR scans (visit 1, visit 2) at least 1 year apart. Patients’ follow‐up ended in August 2018. Clinical data were collected at both visits and included demographics, disease subtype and duration, organ involvement, and current and any change in DMARD and/or vasodilator treatment, including calcium channel blockers (CCBs), iloprost, sildenafil, bosentan, and angiotensin‐converting enzyme inhibitor (ACEI) between the two visits. Iloprost infusion was administered as a 3‐day schedule every 3 months at a dosing regimen of 100 μg, as per Leeds Teaching Hospital National Health Service trust protocol. Serum samples were collected for high‐sensitivity troponin I (hs‐TnI) and N‐terminal pro–brain natriuretic peptide (NT‐proBNP) testing at both visits. hs‐TnI was measured on a Siemens Advia XPT system (Advia Chemistry XPT and Advia Centaur XPT Immunoassay) and NT‐proBNP was measured on Cobas 6000 (immunochemistry module Cobas e601) at both visits. Patients had annual pulmonary function tests (PFTs) performed as part of routine clinical assessment. The PFT measures approximating to each CMR visit were recorded.
Dumitru R.B., Bissell L., Erhayiem B., Fent G., Kidambi A., Abignano G., Greenwood J.P., Biglands J., Del Galdo F., Plein S, & Buch M.H. (2023). Subclinical Systemic Sclerosis Primary Heart Involvement by Cardiovascular Magnetic Resonance Shows No Significant Interval Change. ACR Open Rheumatology, 5(2), 71-80.
Publication 2023
Amino-terminal pro-brain natriuretic peptide Angiotensin-Converting Enzyme Inhibitors Antirheumatic Drugs, Disease-Modifying Bosentan Calcium Channel Blockers Health Services, National Hypersensitivity Iloprost Immunoassay Nesiritide Patients Radionuclide Imaging Serum Sildenafil Treatment Protocols Troponin I Vasodilator Agents
5
Secondary Analysis of ThIlo Trial
The present study was a secondary analysis of the ThIlo trial, a prospective randomized multicenter trial assessing the efficacy of inhaled iloprost for the prevention of the development and progression of ARDS in critically ill patients. Study design and recruitment are described elsewhere [14 (link)]. The study was approved by the Institutional Review Board of the Research Ethics Committee of the University of Tübingen (899/2018AMG1) and the corresponding ethical review boards of all the participating centers. The trial was approved by the Federal Institute for Drugs and Medical Devices (BfArM, EudraCT No. 2016-003168-37) and registered at clinicaltrials.gov (NCT03111212). All patients provided written informed consent prior to enrollment.
Iloprost treatment did not show any significant effect on the outcomes of these patients; therefore, a secondary analysis was performed.
Bernard A., Serna-Higuita L.M., Martus P., Mirakaj V., Koeppen M., Zarbock A., Marx G., Putensen C., Rosenberger P, & Haeberle H.A. (2023). COVID-19 does not influence functional status after ARDS therapy. Critical Care, 27, 48.
Full text: Click here
Publication 2023
Critical Illness Disease Progression Ethical Review Ethics Committees, Research Iloprost Medical Devices Patients Pharmaceutical Preparations Respiratory Distress Syndrome, Adult

Top products related to «Iloprost»

1
Iloprost by Cayman Chemical
Sourced in United States
Iloprost is a laboratory reagent produced by Cayman Chemical. It is a synthetic prostacyclin analogue that functions as a vasodilator and inhibitor of platelet aggregation.
2
Iloprost by Bayer
Sourced in Germany
Iloprost is a lab equipment product manufactured by Bayer. It is a synthetic prostacyclin analogue used in research and scientific applications. The core function of Iloprost is to serve as a laboratory tool for various experimental and analytical purposes.
3
Ilomedin by Bayer
Sourced in Germany
Ilomedin is a medical device used for the administration of intravenous (IV) infusions. It is designed to provide accurate and controlled delivery of liquid medications or solutions to patients. The core function of Ilomedin is to facilitate the delivery of prescribed treatments in a hospital or clinical setting.
4
Cay10441 by Cayman Chemical
Sourced in United States
CAY10441 is a chemical compound that is commonly used as a laboratory reagent. It serves as a functional tool for researchers and scientists in various fields of study. The product information and its core function are presented in a concise, factual, and unbiased manner, without any interpretation or extrapolation on its intended use.
5
Iloprost by Merck Group
Sourced in United States
Iloprost is a laboratory equipment product manufactured by the Merck Group. It is a stable analogue of prostacyclin (PGI2), a naturally occurring substance that plays a role in vascular homeostasis. Iloprost is used in various research and scientific applications, but a detailed description of its intended use is not available.
6
Butaprost by Cayman Chemical
Sourced in United States, Japan
Butaprost is a laboratory product available from Cayman Chemical. It is a synthetic prostaglandin analogue. The core function of Butaprost is to serve as a research tool for the study of prostaglandin-related biological processes.
7
U46619 by Cayman Chemical
Sourced in United States, United Kingdom, Poland
U46619 is a thromboxane A2 receptor agonist. It is a colorless crystalline powder that is soluble in organic solvents.
8
Mre 269 by Cayman Chemical
Sourced in United States
MRE-269 is a laboratory product manufactured by Cayman Chemical. It is a molecular reagent used in scientific research applications. The core function of MRE-269 is to facilitate chemical analysis and experimentation within a laboratory setting.
9
Bw245c by Cayman Chemical
Sourced in United States
BW245C is a laboratory instrument designed for centrifugal separation. It features a temperature-controlled environment and a range of rotor options to accommodate various sample types and volumes.
10
Rnalater by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, Japan, Lithuania, Italy, Australia, Canada, Denmark, China, New Zealand, Spain, Belgium, France, Sweden, Switzerland, Brazil, Austria, Ireland, India, Netherlands, Portugal, Jamaica
RNAlater is a RNA stabilization solution developed by Thermo Fisher Scientific. It is designed to protect RNA from degradation during sample collection, storage, and transportation. RNAlater stabilizes the RNA in tissues and cells, allowing for efficient RNA extraction and analysis.

More about "Iloprost"

Iloprost, a synthetic prostacyclin (PGI2) analog, is a powerful vasodilator and platelet aggregation inhibitor used to treat pulmonary arterial hypertension (PAH) and peripheral artery disease (PAD).
It has been shown to improve exercise capacity and hemodynamic parameters in clinical studies.
Researchers can optimize their Iloprost studies using PubCompare.ai, an AI-driven platform that helps locate protocols from literature, preprints, and patents, while providing accurate comparisons to identify the best protocols and products.
This cutting-edge solution enables reproducible, accurate studies for Iloprost and other therapeutics like Ilomedin, CAY10441, Butaprost, U46619, MRE-269, and BW245C.
PubCompare.ai also integrates data from RNAlater, a RNA stabilization reagent, to ensure high-quality RNA samples for your Iloprost research.
With PubCompare.ai, researchers can optimize their Iloprost studies, leading to more reliable and impactful findings in the treatment of PAH and PAD.